New hope for tough breast cancer: drug combo shows promise in trial
NCT ID NCT02860000
First seen Jan 10, 2026 · Last updated Jun 17, 2026 · Updated 24 times
Summary
This study tested a drug called alisertib, either alone or combined with fulvestrant, in 96 postmenopausal women with advanced breast cancer that had stopped responding to hormone therapy. The goal was to see if these treatments could shrink tumors. Alisertib works by blocking enzymes that help cancer cells grow, while fulvestrant blocks estrogen from fueling the cancer. The trial aimed to find a better way to control the disease in this hard-to-treat group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Georgetown University Medical Center
Washington D.C., District of Columbia, 20007, United States
-
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Montefiore Medical Center
The Bronx, New York, 10461, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
-
Vanderbilt Breast Center at One Hundred Oaks
Nashville, Tennessee, 37204, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.